

APPLICANT(S): DALTON, James T. et al.
SERIAL NO.: 10/849,039
FILED: May 20, 2004
Page 20

REMARKS

Claims 1-95 are pending in the application. Claims 1-32, 35-37, 52-64, 68-75 and 79-81 have been rejected. Claim 69 has been amended.

Claims 33, 34, 38-51, 65-67, 76-78 and 82-95 are withdrawn from consideration as being drawn to the non elected invention.

Applicants respectfully assert that the amendments to the claims add no new matter.

Double Patenting Rejections

In the Office Action, the Examiner rejected claims 1-32, 35-37, 52-64, 68-75 and 79-81 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-85 of U.S. Patent No. 6,838,484 or over claims 1-10 of U.S. Patent No. 6,569,896, or over claims 1-5 of U.S. Patent No. 6,492,554.

Applicants hereby offer to provide a terminal disclaimer upon indication by the Examiner of allowable claims.

CLAIM REJECTIONS

35 U.S.C. § 112 Rejections

In the Office Action, the Examiner rejected claims 63, 69-75 and 79-81 under 35 U.S.C. § 112, as allegedly lacking antecedent basis.

Applicants disagree. Claim 52, 69 and 71 recite *a metabolite* of the SARM compound represented by the structure of formula II, III and IV respectively. Claims 63, 70, 72, 73, 74, 75 and 79 refer to specific metabolites, such as hydroxylated (claims 63, 70, 73, 74, 75), hydrolyzed (claim 72), or methylated (claim 79) metabolites of the SARM compound of formulas II, III or IV.

Best Available Copy

APPLICANT(S): DALTON, James T. et al.
SERIAL NO.: 10/849,039
FILED: May 20, 2004
Page 21

Support for the hydroxylated, methylated or hydrolyzed metabolites claimed can be found throughout the Specification, for example, on pages 25, 30 and 32, in Figures 12 and 15 and in Examples 5 and 6. Applicants maintain that sufficient antecedent basis is thus provided and accordingly request withdrawal of the rejection of claims 63, 69-75 and 79-81.

35 U.S.C. § 103 Rejections

In the Office Action, the Examiner rejected claims 1-32, 35-37, 52-64, 68-75 and 79-81 under 35 U.S.C. § 103(a), as allegedly being rendered obvious in view of Tucker (US 4,636,505) or Miller et al (US 6,019,957).

Applicants disagree. Applicants maintain that Miller is disqualified as a reference under 35 U.S.C. 103(a), as the subject matter described in Miller and that claimed in the subject Application were commonly owned at the time the invention of the subject Application was made. Applicants herein submit a statement issued by the attorney of record indicating the common ownership by the University of Tennessee Research Corporation of the subject matter described in Miller et al. and that claimed in the subject Application. Accordingly, Applicants request withdrawal of the rejection.

Furthermore, the Examiner rejected claims 1-32, 35-37, 52-64, 68-75 and 79-81 under 35 U.S.C. § 103(a), as allegedly being rendered obvious in view of Tucker (US 4,636,505).

Applicants disagree. Claims 1, 52, 69, and dependents therefrom, recite *metabolites* of the SARM compounds represented by formulas I, II, III, IV, VII, VIII, IX, X. The metabolites of compounds of formulas I, II, III, IV, VII, VIII, IX, X, are produced as a result of *in-vivo* metabolic processing of the compounds, to yield, *inter-alia*, oxidized, hydrolyzed, and methylated forms of the compounds of formulas I, II, III, IV, VII, VIII, IX, X.

Tucker does not describe, nor provide any foundation for the claimed metabolites of the instant invention. It would not be obvious, based on the US '505, to arrive at the claimed metabolites of the instant invention, or compositions comprising the same. Accordingly, Applicants request withdrawal of the rejection.

In view of the foregoing amendments and remarks, the pending claims are deemed to be allowable. Their favorable reconsideration and allowance is respectfully requested.


Best Available Copy

APPLICANT(S): DALTON, James T. et al.
SERIAL NO.: 10/849,039
FILED: May 20, 2004
Page 22

Should the Examiner have any question or comment as to the form, content or entry of this Amendment, the Examiner is requested to contact the undersigned at the telephone number below. Similarly, if there are any further issues yet to be resolved to advance the prosecution of this application to issue, the Examiner is requested to telephone the undersigned counsel.

Please charge any fees associated with this paper to deposit account No. 50-3355.

Respectfully submitted,



Mark S. Cohen
Attorney/Agent for Applicant(s)
Registration No. 42,425

Dated: April 26, 2006

Pearl Cohen Zedek Latzer, LLP
1500 Broadway, 12th Floor
New York, New York 10036
Tel: (646) 878-0800
Fax: (646) 878-0801

Best Available Copy